Mild to Moderate Renal Impairment Is Associated with No-Reflow Phenomenon after Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction

Angiology

Volumn 66, Issue 7, 2015, Pages 644-651

  Kurtul, Alparslan ^a   Murat, Sani Namik ^a   Yarlioglues, Mikail ^a   Duran, Mustafa ^a   Celik, Ibrahim Etem ^a   Kilic, Alparslan ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

acute myocardial infarction; estimated glomerular filtration rate; no reflow phenomenon; primary percutaneous coronary intervention

Indexed keywords

CREATININE; GLUCOSE; HEMOGLOBIN; TROPONIN T; URIC ACID; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYNTAX SCORE; URIC ACID BLOOD LEVEL; ANGIOCARDIOGRAPHY; BLOOD; ECHOCARDIOGRAPHY; ECHOGRAPHY; MIDDLE AGED; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PATHOPHYSIOLOGY; RADIOGRAPHY; RENAL INSUFFICIENCY;

BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; ECHOCARDIOGRAPHY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; RENAL INSUFFICIENCY;

EID: 84937913526     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319714546738     Document Type: Article

References (40)

1. Grines CL, Browne KF, Marco J,. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The primary angioplasty in myocardial infarction study group. N Engl J Med. 1993; 328 (10): 673-679.
2. Stone GW, Peterson MA, Lansky AJ, Dangas G, Mehran R, Leon MB,. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol. 2002; 39 (4): 591-597.
3. Morishima I, Sone T, Okumura K,. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol. 2000; 36 (4): 1202-1209.
4. Lee CH, Tse HF,. Microvascular obstruction after percutaneous coronary intervention. Catheter Cardiovasc Interv. 2010; 75 (3): 369-377.
5. Rezkella SH, Dharmashankar KC, Abdalrahman IB, Kloner RA,. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome and effect of pharmacologic therapy. J Interv Cardiol. 2010; 23 (5): 429-436.
6. Rezkalla SH, Kloner RA,. No-reflow phenomenon. Circulation. 2002; 105 (5): 656-662.
7. Gür M, Türkolu C, Taşkln A,. Paraoxonase-1 activity and oxidative stress in patients with anterior ST elevation myocardial infarction undergoing primary percutaneous coronary intervention with and without no-reflow. Atherosclerosis. 2014; 234 (2): 415-420.
8. Galasso G, Schiekofer S, DAnna C,. No-reflow phenomenon: pathophysiology, diagnosis, prevention, and treatment. A review of the current literature and future perspectives. Angiology. 2014; 65 (3): 180-189.
9. Smith GL, Masoudi FA, Shlipak MG, Krumholz HM, Parikh CR,. Renal impairment predicts long-term mortality risk after acute myocardial infarction. J Am Soc Nephrol. 2008; 19 (1): 141-150.
10. Campbell NG, Varagunam M, Sawhney V,. Mild chronic kidney disease is an independent predictor of long-term mortality after emergency angiography and primary percutaneous intervention in patients with ST-elevation myocardial infarction. Heart. 2012; 98 (1): 42-47.
11. Akkaya E, Ayhan E, Uyarel H,. The impact of chronic kidney disease on in-hospital clinical outcomes in patients undergoing primary percutaneous angioplasty for ST-segment elevation myocardial infarction. Turk Kardiyol Dern Ars. 2011; 39 (4): 276-282.
12. Anavekar NS, McMurray JJ, Velazquez EJ,. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004; 351 (13): 1285-1295.
13. Annuk M, Soveri I, Zilmer M, Lind L, Hulthe J, Fellström B,. Endothelial function, CRP and oxidative stress in chronic kidney disease. J Nephrol. 2005; 18 (6): 721-726.
14. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39 (2 suppl 1): S1-S266.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999; 130 (6): 461-470.
16. Thrombolysis In Myocardial Infarction (TIMI) trial, phase I findings: TIMI study groups. N Engl J Med. 1985; 312 (14): 932-936.
17. Hong SN, Ahn Y, Hwang SH,. Usefulness of preprocedural N-terminal pro-brain natriuretic peptide in predicting angiographic no-reflow phenomenon during stent implantation in patients with ST-segment elevation acute myocardial infarction. Am J Cardiol. 2007; 100 (4): 631-614.
18. Ito H,. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med. 2006; 3 (9): 499-506.
19. Manciet LH, Poole DC, McDonagh PF, Copeland JG, Mathieu-Costello O,. Microvascular compression during myocardial ischemia: mechanistic basis for no-reflow phenomenon. Am J Physiol. 1994; 266 (4 pt 2): 1541-1550.
20. Simes RJ, Topol EJ, Holmes DR Jr,. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation. 1995; 91 (7): 1923-1938.
21. Ndrepepa G, Tiroch K, Fusaro M,. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010; 55 (21): 2383-2389.
22. Nerpin E, Ingelsson E, Risérus U,. Association between glomerular filtration rate and endothelial function in an elderly community cohort. Atherosclerosis. 2012; 224 (1): 242-246.
23. Stam F, van Guldener C, Becker A,. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J Am Soc Nephrol. 2006; 17 (2): 537-545.
24. Kielstein JT, Böger RH, Bode-Böger SM,. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 1999; 10 (3): 594-600.
25. Astrup AS, Tarnow L, Pietraszek L,. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care. 2008; 31 (6): 1170-1176.
26. Sen N, Ozlu MF, Akgul EO,. Elevated plasma asymmetric dimethylarginine level in acute myocardial infarction patients as a predictor of poor prognosis and angiographic impaired reperfusion. Atherosclerosis. 2011; 219 (1): 304-310.
27. Kaysen GA,. Inflammation: cause of vascular disease and malnutrition in dialysis patients. Semin Nephrol. 2004; 24 (5): 431-436.
28. Celik T, Iyisoy A, Yuksel UC, Jata B, Ozkan M,. The impact of admission C-reactive protein levels on the development of no-reflow phenomenon after primary PCI in patients with acute myocardial infarction: the role of inflammation. Int J Cardiol. 2009; 136 (1): 86-88.
29. Oduncu V, Tanalp AC, Erkol A,. Impact of chronic pre-treatment of statins on the level of systemic inflammation and myocardial perfusion in patients undergoing primary angioplasty. Am J Cardiol. 2011; 107 (2): 179-185.
30. Soylu K, Yuksel S, Gulel O,. The relationship of coronary flow to neutrophil/lymphocyte ratio in patients undergoing primary percutaneous coronary intervention. J Thorac Dis. 2013; 5 (3): 258-264.
31. McCullough PA,. Why is chronic kidney disease the spoiler for cardiovascular outcomes? J Am Coll Cardiol. 2003; 41 (5): 725-728.
32. Filiopoulos V, Vlassopoulos D,. Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. Inflamm Allergy Drug Targets. 2009; 8 (5): 369-382.
33. Cottone S, Lorito MC, Riccobene R,. Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. J Nephrol. 2008; 21 (2): 175-179.
34. Shah SV, Baliga R, Rajapurkar M, Fonseca VA,. Oxidants in chronic kidney disease. J Am Soc Nephrol. 2007; 18 (1): 16-28.
35. Landray MJ, Wheeler DC, Lip GY,. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis. 2004; 43 (2): 244-253.
36. Charron T, Jaffe R, Segev A,. Effects of distal embolization on the timing of platelet and inflammatory cell activation in interventional coronary no-reflow. Thromb Res. 2010; 126 (1): 50-55.
37. Mikhailidis DP, Athyros VG,. Acute kidney injury: short-term statin therapy for prevention of contrast-induced AKI. Nat Rev Nephrol. 2014; 10 (1): 8-9.
38. Au TH, Bruckner A, Mohiuddin SM, Hilleman DE,. The prevention of contrast-induced nephropathy [published online July 3, 2014]. Ann Pharmacother. 2014.
39. Abe M, Morimoto T, Akao M,. Relation of contrast-induced nephropathy to long-term mortality after percutaneous coronary intervention. Am J Cardiol. 2014; 114 (3): 362-368.
40. Gandhi S, Mosleh W, Abdel-Qadir H, Farkouh ME,. Statins and contrast-induced acute kidney injury with coronary angiography: systematic review and meta-analysis [published online May 19, 2014]. Am J Med. 2014.